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Abstract
Accurate biomarkers of Mycobacterium tuberculosis infection activity would significantly improve early diagnosis, treatment
and management of M. tuberculosis infection. We hypothesised that circulating B-lymphocytes may be useful biomarkers of
tuberculosis (TB) infection status in highly TB-endemic settings. Ex-vivo and in-vitro mycobacteria-specific B-cell ELISPOT
assays were used to examine the plasmablast (PB) and memory B-cell (MBC) responses in the peripheral blood of adult,
healthy, community controls (n = 151) and of active TB patients (n = 48) living in Uganda. Frequencies of mycobacteria-
specific PBs were markedly higher in active TB patients compared to healthy controls, and, conversely, MBCs were markedly
higher in the healthy controls compared to active TB patients. In addition, the community controls with evidence of latent
TB infection had higher peripheral blood PB and MBC responses than those without evidence of TB infection. These data
demonstrate that peripheral blood B-cell responses are differentially modulated during latent and active M. tuberculosis
infection, and suggest that the PB to MBC ratio may be a useful biomarker of TB infection activity.
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Introduction
Until recently, tuberculosis (TB) was defined as a two-stage
infection - active or latent. In contrast, current thinking suggests
that TB may induce a broad spectrum of immune responses,
dependent on the Mycobacterium tuberculosis load and/or
replication activity within infected individuals, so that the interplay
of mycobacterial replication and host immune response results in
disease, recovery from active infection, or a sub-clinical latent state
[1–4]. Understanding the interplay between M. tuberculosis and
host immune responses within this clinical spectrum remains a
critical research goal [5,6]. In addition, identification of biomark-
ers that can accurately predict the clinical status of M. tuberculosis
infected individuals, and identify those who are at the highest risk
of progressing from sub-clinical latent infections to clinically
manifested active disease, also remains a fundamental challenge
[5–10]. Novel transcriptomic approaches have improved our
knowledge of the immune response to, and pathogenesis of, TB,
providing new insight into potential biological markers that might
eventually stratify M. tuberculosis infected individuals [7,11,12].
One major break-through from such approaches indicated a
relationship between a type 1-interferon inducible gene signature
and disease activity as assessed by chest x-ray [13]. Interestingly, in
this paper the healthy latent TB infected individuals had gene
signatures that clustered with both active TB and healthy control
gene signatures. The authors suggested that the healthy latent TB
infected individuals with gene signatures clustering with those of
active TB, might be the ones about to develop active TB, although
they did not prove this hypothesis in this paper. Subsequently,
other studies have reported changes in gene expression profiles of
other signatures within whole blood of TB patients before and
after treatment, as well as in latently infected individuals and
healthy controls [11,14,15]. Although these approaches have
generated exciting results, the cost and expertise needed to
produce accurate results limit their practicability and efficiency,
particularly in highly endemic and resource poor settings. Cheap,
simplified, rapid and accurate alternatives to these approaches are
therefore still needed.
Given the critical role of T-cells in M. tuberculosis immunity,
approaches aiming to identify new TB biomarkers have previously
been biased towards T-cells and T-cell associated molecules.
However, recent reports suggesting various modulatory roles for
B-cells in M. tuberculosis-specific immune responses [16–21] have
revitalised interest in B-cells as possible targets for new biomarkers
[14,15]. In a previous study, we described higher frequencies of
MBCs within the peripheral blood of healthy UK-donors who had
previously visited or lived in highly TB-endemic areas compared
to their counterparts who had neither visited nor stayed in such
areas [22]. More recently, active TB patients who were
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successfully cured following treatment were found to present
contrasting B-cell associated gene expression patterns within their
blood, before and after treatment [14].
In the present study, we investigated whether the ratio of
plasmablasts (PBs) to memory B-cells (MBCs) may accurately
predict the clinical status of M. tuberculosis infected individuals
living in a highly TB-endemic area. Plasmablasts are short-lived
antibody secreting cells (ASCs) and are readily detected in
peripheral blood during an early or on-going active infection,
but they are rarely present in the circulation in the absence of
antigen and, or, of viable, replicating pathogens [23]. In contrast,
MBCs are long-lived and may persist throughout the lifetime of
the host [23–27]. MBCs rapidly and specifically respond to
antigenic re-stimulation, differentiating into new ASC populations
[27–30]. Given their prolonged lifespan and rapid response,
MBCs may contribute to the rapid clearance of pathogens
following re-exposure throughout the host’s lifetime [24,25],
although this has not been demonstrated for infection with M.
tuberculosis. Nevertheless, the B cell response to infection with M.
tuberculosis may be promising in predicting the immunological
(and consequently clinical) status of M. tuberculosis infected
individuals. We reasoned that the presence of antigen-specific PBs
in the absence of MBCs within the peripheral circulation may
reflect a current or on-going active M. tuberculosis infection
(clinically manifested disease); that the presence of PBs in addition
to MBCs may reflect a resolving active or a subclinical latent
infection; and that the presence of MBCs in the absence of PBs
may reflect sterile immunity following infection and thus a healthy
state.
Results
PB and MBC responses to M. tuberculosis antigens
Little is known about the peripheral blood B-cell responses
induced by M. tuberculosis infection. We therefore examined these
responses by employing short-term ex-vivo and 6-day in-vitro
ELISPOT assays to determine Mycobacteria-specific PB and MBC
responses, respectively, in the peripheral blood of adult, healthy,
community controls (n = 151) and active TB patients (n = 48). PB
and MBC responses were present and readily detected within the
peripheral blood of these individuals (Figure 1). Of the 116 healthy
controls tested for MBC responses, 74 had positive MBC responses
to PPD, 84 to ESAT-6, 76 to CFP-10 and 74 to Ag85A
(Figure 1A, open circles). Of another 35 healthy controls tested for
PB response, three participants had positive PB responses to PPD,
five to ESAT-6, four to CFP-10 and four to Ag85A (Figure 1A,
closed circles). Conversely, of the 18 active TB patients tested for
MBC responses, five had positive responses to PPD, 10 to ESAT-
6, six to CFP-10 and five to Ag85A (Figure 1B). Of another 30
active TB cases, tested for PB responses, 24 had positive PB
responses to PPD, 27 to ESAT-6, 25 to CFP-10 and 24 to Ag85A
(Figure 1B). Healthy community controls had significantly higher
frequencies of mycobacteria-specific MBCs than of PBs (Figure 1A
and Figure S1A), and active TB patients had significantly higher
frequencies of mycobacteria-specific PBs than of MBCs (Figure 1B
and Figure S1B). We observed strong correlations amongst the
detected antigen-specific PB and MBC responses, (Table 1),
showing that individuals who responded to any one antigen were
likely to respond to all antigens tested.
Differential modulation of Mycobacteria-specific PB and
MBC responses during M. tuberculosis infection
Healthy community controls were not assessed for latent TB
infection using conventional assays such as the tuberculin skin test
(TST) or interferon-gamma release assays (IGRAs). Thus,
participants in this group may have been latently infected or truly
TB-naı¨ve. To explore this possibility, we stratified our community
controls into those who had responses to ESAT-6 or CFP-10
(n = 89) and those who lacked responses to both these M.
tuberculosis – specific antigens (n = 26) in either of the two B-cell
assays. We then compared the PB and MBC responses detected in
these individuals to those detected in the active TB patients.
Consistent with our hypothesis, and as described above, high PB
numbers were characteristic of active TB patients, although MBCs
were also detected within their peripheral blood (Figure 2, filled
circles). On the other hand, high MBC numbers to PPD and
Ag85A were characteristic of healthy individuals with responses to
ESAT-6 or CFP-10, although a few PBs were detected in some
individuals (Figure 2, half filled triangles). All healthy individuals
lacking responses to both ESAT-6 and CFP-10 also lacked PB
responses to PPD and Ag85A, and only low numbers of MBCs
were present within their peripheral blood (Figure 2, open circles).
This data is consistent with the generally held definition that
healthy individuals with responses to ESAT-6 and CFP-10 are
latently infected, and those lacking responses to both of these
antigens are uninfected [31]. For the purpose of our further
analyses, by analogy with T-cell, IGRAs [31], we defined
individuals who had a response to either of the two M. tuberculosis
– specific antigens in either B-cell assay as having probable latent
TB infection. Together, these data demonstrate that peripheral
blood B-cell responses are differentially modulated during latent
and active M. tuberculosis infection, and that the frequencies of M.
tuberculosis-specific PBs and MBCs in peripheral blood may be
able to accurately predict the clinical status of M. tuberculosis
infected individuals living in highly TB-endemic settings.
The ratio of mycobacteria-specific PBs to MBCs is likely to
be associated with M. tuberculosis clinical status
Having observed contrasting peripheral blood PB and MBC
responses in the community controls and active TB patients, we
next considered that the ratio of PBs to MBCs (PB:MBC) might be
a more accurate approach for predicting the clinical status of M.
tuberculosis infected individuals. Considering that we conducted
most of our assays in different individuals, we could not directly
assess this approach. Nevertheless, we reasoned that comparing
median PB and MBC responses in active TB patients to those in
the latently infected or uninfected community controls might
reveal a pattern that would reflect likely PB:MBC ratios. Indeed,
we observed that the median antigen-specific PB response was
higher in the TB patients than in the uninfected and latently
infected controls, but also higher in the latently infected than in the
uninfected controls (Table 2). In contrast, the median antigen-
specific MBC response was higher in the latently infected controls
than in the active TB patients and uninfected controls (Table 2).
This data further suggests that PBs may be associated with an
active TB phenotype and MBCs with a latent state. To explore
this further, we analysed data from the group of 35 healthy
community controls for whom we had data on both PB and MBC
responses (Figure 3). The majority of these healthy participants
had more peripheral blood MBCs than PBs, presenting a low
PB:MBC ratio (Figure 3). Of interest, one participant, who had
not been BCG-vaccinated, presented with a ratio consistent with
that of the active TB patients (Figure 3, indicated with an open
square). We postulate that this individual may be more at risk of
developing active TB infection than the other healthy volunteers,
or may be progressing from latency towards active disease.
Together, these data suggest that the ratio of M. tuberculosis-
specific PBs to MBCs in peripheral blood may predict the clinical
B-Cells as TB Biomarkers
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status of M. tuberculosis infected individuals, and thus could be a
useful biomarker of M. tuberculosis infection status, particularly in
individuals living in highly TB-endemic settings.
Discussion
We have shown that peripheral blood mycobacteria-specific B-
cell responses are differentially modulated during active and latent
M. tuberculosis infection - PB responses are significantly elevated
whereas MBC responses are depleted from the peripheral
circulation during active TB disease. These observations may be
explained by the increase in mycobacterial loads due to the
presence of viable replicating mycobacteria within these TB
patients. These elevated mycobacterial loads may activate
circulating mycobacteria-specific MBCs, which subsequently
differentiate into new PB populations, and thus contribute to the
elevation of PBs detected within the peripheral blood of active TB
patients. In addition, the increase in mycobacterial loads may
accelerate the activation and differentiation of naive B-cells,
thereby contributing to the PB pool. Plasmablasts contribute to the
increase in serum levels of protective antibodies during active
infection, regardless of the pathogen. Increased serum antibodies
are readily detected during TB infection [32,33], although why
such antibodies are not protective remains unknown.
It should be noted that we used frozen PBMCs from active TB
patients and fresh PBMCs from healthy volunteers in our
experiments. There is some suggestion that the freeze/thaw cycle
may affect cell viability and/or a selective loss of cell populations,
notably activated cells [34,35]. Given this potential issue, we might
expect the freeze/thaw process to selectively reduce numbers of
PBs, which are activated B cells; however, we could clearly identify
PB populations in our thawed PBMCs from active TB patients.
Thus, if the freeze/thaw process did negatively affect PB numbers,
we are likely to have underestimated the high PB:MBC ratio in
these patients. In addition, a recent study showed that the freeze/
thaw process did not affect influenza-specific PB numbers [36],
and in a more recent report, MBC responses were also largely
unaffected by this process [37]. It is therefore likely that the freeze/
thaw process did not significantly alter the numbers of PBs or
MBCs that we report here.
Our study lacked conventional tests such as the TST or an
IGRA that could independently confirm latent TB infection
(LTBI) in our healthy controls. Nevertheless, our data is consistent
with what we might expect from such assays: the proposed LTBI
Figure 1. Mycobacteria-specific PB and MBC responses in the healthy community controls and active TB cases. Frequencies of antigen-
specific PBs and MBCs were determined by 6-hour ex-vivo and 6-day in-vitro ELISPOTs respectively. Frequencies of antigen-specific PBs and MBCs are
presented as antibody secreting cells per million PBMCs. Frequencies of mycobacteria-specific MBCs (open circles) and PBs (closed circles) in the
healthy community controls (A) and active TB patients (B) are shown. ***, P,0.001; **, P,0.01.
doi:10.1371/journal.pone.0106796.g001
Table 1. Correlations among paired antigen-specific PB and MBC responses detected in the community controls and TB patients.
Association
Spearman’s coefficient (r)
MBCs Healthy/TB patients P-value
Spearman’s coefficient (r)
PBs Healthy/TB patients P-value
PPD and ESAT-6 0.65/0.65 ,0.0001/0.0032 0.74/0.63 ,0.0001/0.0002
PPD and Ag85A 0.59/0.44 ,0.0001/0.0704 0.77/0.52 ,0.0001/0.0035
PPD&CFP-10 0.66/0.67 ,0.0001/0.0022 0.40/0.63 0.0166/0.0002
ESAT-6 and Ag85A 0.79/0.80 ,0.0001/,0.0001 0.72/0.87 ,0.0001/,0.0001
ESAT-6 and CFP-10 0.70/0.81 ,0.0001/,0.0001 0.27/0.63 0.1163/0.0002
CFP-10 and Ag85A 0.68/0.67 ,0.0001/0.0024 0.30/0.77 0.0784/,0.0001
doi:10.1371/journal.pone.0106796.t001
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Figure 2.Mycobacteria-specific PB and MBC responses in the active TB patients and community controls. Frequencies of antigen-specific
PBs and MBCs were determined by 6-hour ex-vivo and 6-day in-vitro ELISPOTs respectively. Frequencies of antigen-specific PBs and MBCs are
presented as antibody secreting cells per million PBMCs. (A) Frequencies of mycobacteria-specific PBs in the active TB patients (filled circles),
community controls responding to ESAT-6/CFP-10 (half filled triangles) and healthy community controls lacking ESAT-6 and CFP-10 responses (open
circles) (B) Frequencies of mycobacteria-specific MBCs in the active TB patients (filled circles), community controls responding to ESAT-6/CFP-10 (half
filled triangles) those without ESAT-6 and CFP-10 responses (open circles). **** P,0.0001, ***, P,0.001; **, P,0.01.
doi:10.1371/journal.pone.0106796.g002
Figure 3. Pairedmycobacteria-specific PB and MBC responses in healthy community controls.Matched frequencies of antigen-specific PBs
and MBCs were determined by 6-hour ex-vivo and 6-day in-vitro ELISPOTs respectively. Matched frequencies of PPD- (A), ESAT-6- (B), CFP-10- (C),
Ag85A- (D) and Ag85B- (E) specific PBs and MBCs in healthy community controls are shown. Open square across all panels represents an interesting
donor who presented with a higher PB:MBC ratio on various antigens tested. Frequencies of antigen-specific PBs and MBCs are presented as antibody
secreting cells per million PBMCs.
doi:10.1371/journal.pone.0106796.g003
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group showed responses to ESAT-6 and/or CFP10, whereas the
LTBI negative group did not. In particular, the marked lack of B-
cell responses to any mycobacterial antigens in those individuals
with no TB-specific B-cell responses (Figure 2A and Table 2)
suggests that these individuals are indeed M. tuberculosis naı¨ve.
Considering the relatively high prevalence of non-tuberculous
mycobacteria (NTM) in sub-Saharan Africa, some of the responses
to ESAT-6 and/or CFP-10 detected in the LTBI group may be
attributed to previous exposure to such mycobacterial species.
Although this possibility cannot be ruled out completely, it is worth
noting that the prevalence of infection with such mycobacterial
species in these settings is much lower compared to that of M.
tuberculosis [38], suggesting that M. tuberculosis infection or
exposure dominates these B-cell responses.
Our data suggests a potential role for M. tuberculosis-specific
peripheral blood B-cell responses as biomarkers of TB infection.
We propose that the M. tuberculosis-specific PB:MBC ratio may
serve as a valuable and early diagnostic marker for both latent and
active TB infections in humans. We envision that the changes in
the frequency of PBs or peripheral blood PB-specific responses
might be an accurate way to identify an immediate and active
immune response, and thus may be a useful predictor of an
individual who is currently exposed to replicating M. tuberculosis.
If we are correct, then the raised PB:MBC ratio observed across
some antigens in a single healthy community control may be
particularly significant (Figure 3). Although we were unable to
follow up this individual during the course of this study, our
hypothesis would suggest that individuals of this phenotype may be
progressing towards active, clinical disease. Clearly, further
prospective studies need to be done before definitive conclusions
can be made. Such studies may lead to the accurate detection of
discreet stages of infection within latently infected individuals, as
has been proposed [1], and subsequently to early identification of
those individuals who are most likely to progress to a clinically
manifested active disease. Such individuals would then be the
obvious targets for directed chemoprophylaxis.
Concluding Remarks
This study investigated whether differences in peripheral blood
B-cell responses accurately reflect the clinical status of M.
tuberculosis infected individuals. We demonstrate a differential
modulation in peripheral blood PB and MBC responses during
active and latent M. tuberculosis infection, reflected in a significant
increase in the peripheral blood PB:MBC ratio during active M.
tuberculosis infection. We conclude that the ratio of M.
tuberculosis-specific PBs to MBCs within the peripheral blood
may be a useful biomarker of TB infection activity and thus
warrants further investigation. Prospective studies aiming to test
the kinetics of this ratio among untreated, M. tuberculosis latently
infected individuals who might progress towards active infection,
or in newly identified active TB patients undergoing treatment,
may provide better insight and validation of this concept. This
may thus serve as a significant improvement to currently available
methods for detecting M. tuberculosis infection, which cannot
accurately distinguish between active and latent infections.
Materials and Methods
Ethics statement
The ethics committees at Makerere University, Kampala,
Uganda, the Uganda Virus Research Institute (UVRI) and the
Uganda National Council of Science and Technology (UNCST)
approved these studies. Informed written consent was obtained
from all study participants. Participants provided up to 20 ml of
heparinised venous blood that was used in subsequent experi-
ments.
Study participants
Forty-eight (48) newly diagnosed, adult, BCG-vaccinated, HIV
negative, untreated, sputum positive TB patients, 18–50 years of
age, were included from a larger prospective study, at two health
clinics in Kampala, Uganda. In addition, 151 adult, HIV negative,
clinically healthy, community controls, 18–55 years old, were
recruited through an HIV counselling and testing programme at
the UVRI clinic in Entebbe, Uganda, as part of a cross-sectional
study. Of the 151 healthy community controls recruited, only four
had not been previously vaccinated with BCG.
Antigens and mitogens
Mycobacterium tuberculosis ESAT-6 (NR-14868), CFP-10 (NR-
14869), Ag85A (NR-14871) and Ag85B (NR-14870) were
obtained through BEI Resources (NIAID, USA) and purified
protein derivative for in-vitro use (PPD) from Statens Serum
Institut (SSI, Denmark). Non-adsorbed tetanus toxoid (TT) was
obtained from the National Institute for Biological Standards and
Control (NIBSC), UK. Phytolacca americana Pokeweed mitogen
(PWM) and Staphylococcus aureus Cowan (SAC) were obtained
from Sigma-Aldrich, UK. CpG-oligonucleotide (ODN-2006, 59-
tcgtcgttttgtcgttttgtcgtt-39) was obtained through Eurofins MWG/
Operon, Germany.
Study design
In-vitro and ex-vivo B-cell ELISPOT assays were used to
examine the mycobacteria-specific memory B cell (MBC) and
plasmabast (PB) responses, respectively, in both active TB patients
and the healthy community controls. Peripheral blood mononu-
clear cells (PBMCs) were isolated by Ficoll Paque Plus (Amersham
Pharmacia Biotech, UK) density-gradient centrifugation, washed
twice in Hank’s balanced salt solution (HBSS, Invitrogen, UK) and
resuspended in RPMI-1640 culture media (Invitrogen, UK)
Table 2. Median PB and MBC responses in the community controls and active TB patients.
Antigen Median antigen-specific cells per 10
6 PBMCs (median PBs/median MBCs)
Healthy LTBI Active
Ag85A 0/0 11/14 20/1
CFP-10 0/0 0/13 14/0
ESAT-6 0/0 13/23 27/5
PPD 0/0 11/10 12/2
doi:10.1371/journal.pone.0106796.t002
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containing 10% Fetal Bovine Serum (FBS), 100 U/ml penicillin,
100 mg/ml streptomycin and 2 mM L-glutamine (all from Sigma-
Aldrich, UK). Purified PBMCs from the blood of the active TB
patients were stored in liquid nitrogen until used; those from the
healthy community controls were used fresh in the ELISPOT
assays. In-vitro ELISPOT assays were used to determine MBC
responses in 116 healthy community controls. Separately, paired
ex-vivo and in-vitro ELISPOT assays were used to determine
matched PB and MBC responses in PBMCs from another 35
clinically healthy participants. For the active TB patients, PBMCs
from 30 participants were analyzed using the ex-vivo ELISPOT to
determine their PB responses. PBMCs from another 18 active TB
cases were analyzed using the in-vitro ELISPOT assay to
determine their MBC response. Due to limited blood volumes
and PBMC numbers obtained from the active TB patients, we
were unable to conduct both assays on samples from the same
patient.
In-vitro ELISPOT assay
Frequencies of MBCs in peripheral blood were determined
using an in-house in-vitro B-cell enzyme-linked immunosorbent
spot (ELISPOT), previously described [22]. Briefly, purified
PBMCs (1x106/ml) were stimulated with a cocktail of 6 mg/ml
CpG, 0.5 mg/ml PWM, 1.2 mg/ml SAC, 25 ng/ml recombinant
human IL-10 (R&D systems, UK) and 50 mM b-mercaptoethanol
for six days at 37uC in a humidified 5% CO2 incubator. Polyclonal
stimulated cells (4x105 cells/ml) were then transferred directly into
wells of a 96-well filter plate (Millipore, MAHAS4510) that was
coated with either 100 ml of PBS containing Mycobacterium-
specific recombinant proteins (6 mg/ml PPD, 10 mg/ml ESAT-6,
Ag85A, Ag85B, and CFP-10), 2 mg/ml Tetanus toxoid (TT,
positive control) or with PBS alone (negative control). Plates were
developed with a biotin-SP-conjugated AffiniPure fragment
donkey anti-human IgG (Jackson ImmunoResearch), strepavidin-
AKP (BD biosciences) and its substrate (AP-conjugate substrate kit,
Biorad, USA). Developed spots were counted using an AID
ELISPOT reader (AID Diagnostika, Germany) and AID ELI-
SPOT software (version 7.0). The frequencies of antigen-specific
MBCs are presented as spot counts per million stimulated PBMCs.
A positive ELISPOT response was defined as the presence of two
or more spots in each replicate well, with the total number of spots
in antigen coated wells being at least twice that observed in the
PBS-coated wells that had no more than five spots.
Ex-vivo ELISPOT assay
Short term ex-vivo ELISPOTs were used to determine the
frequencies of antigen-specific IgG secreting plasmablasts in
peripheral blood of TB patients and healthy controls. Ninety-six
(96) ELISPOT- well filter plates (MAHA S4510, Millipore) were
coated overnight with either 100 ml of PBS containing mycobac-
terium-specific recombinant proteins (6 mg/ml PPD, 10 mg/ml
ESAT-6, Ag85A, Ag85B, and CFP-10). Tetanus toxoid (2 mg/ml)
was used as positive control while PBS-coated wells served as
negative controls. Plates were washed and blocked with RPMI
containing 1% BSA at 37uC for 2 hours. Purified PBMCs (2x105/
ml) were added into each antigen-coated well and the plates were
incubated for 5 hours at 37uC in a 5% CO2 incubator. Plates were
washed with PBS and 0.05% PBS-Tween and developed with
biotin-SP-conjugated AffiniPure fragment donkey anti-human IgG
(Jackson ImmunoResearch), strepavidin- AKP (BD biosciences)
and its substrate (AP-conjugate substrate kit, Biorad, USA).
Developed plates were air-dried and the number of resultant
spots enumerated on an AID ELISPOT reader. Frequencies of
antigen-specific PBs were calculated and later presented as spot
forming units per million PBMCs.
Statistical analysis
Collected data were entered into Excel and GraphPad Prism
software. Statistical analysis was performed using Stata 10.1.
Frequencies of PBs and MBCs were not normally distributed and
therefore non-parametric statistical tests were used. Comparisons
of antigen-specific PB and MBC responses between healthy
community controls and TB patients were made using an
unpaired Wilcoxon sign rank test. Matched PB and MBC
responses in a selected set of healthy community controls were
compared using a paired Wilcoxon sign rank test. Spearman’s
rank correlation coefficient was used to test for correlations
amongst various antigen-specific PB and MBC responses. Only
statistically significant differences are shown.
Supporting Information
Figure S1 Mycobacteria-specific PB and MBC respons-
es in the healthy community controls and active TB
cases. Frequencies of antigen-specific PBs and MBCs were
determined by 6-hour ex-vivo and 6-day in-vitro ELISPOTs
respectively. Frequencies of antigen-specific PBs and MBCs are
presented as antibody secreting cells per million PBMCs.
Frequencies of mycobacteria-specific PBs in healthy community
controls (open circles) and active TB patients (closed circles) (A)
and MBCs in healthy community controls (open circles) and active
TB patients (closed circles) (B) are shown. ****, P,0.0001 ***, P,
0.001; **, P,0.01, *, P,0.05.
(TIF)
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